Oruka Therapeutics (ORKA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
ORKA dips 2.6% to $71.93, a 3-month low, 5 down days in a row. Closed at $71.93, -2.63% vs the prior close of $73.87. Day range $70.50–$74.26, opened at $73.45.
ORKA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ORKA dips 2.6% to $71.93, a 3-month low, 5 down days in a row
- Closed at $71.93, -2.63% vs the prior close of $73.87. Day range $70.50–$74.26, opened at $73.45.
- Volume was 1.39M shares, 1.6x its 50-day average of 895.35K.
- Price is -22.3% vs its 50-day average ($92.57) and +8.5% vs its 200-day average ($66.32).
- 52-week range $25.11–$115.52; today's close sits at 52% of that range, 37.7% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — ORKA slides 3.7% to $73.87, a 3-month low, 4 down days in a row
- Closed at $73.87, -3.66% vs the prior close of $76.68. Day range $73.15–$77.89, opened at $75.53.
- Volume was 1.22M shares, 1.4x its 50-day average of 883.70K.
- Price is -20.7% vs its 50-day average ($93.10) and +11.7% vs its 200-day average ($66.11).
- 52-week range $25.11–$115.52; today's close sits at 54% of that range, 36.1% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — ORKA dips 1.9% to $76.68, a 3-month low, 3 down days in a row
- Closed at $76.68, -1.93% vs the prior close of $78.19. Day range $75.41–$78.57, opened at $77.37.
- Volume was 685.30K shares, 0.8x its 50-day average of 882.42K.
- Price is -18.1% vs its 50-day average ($93.57) and +16.4% vs its 200-day average ($65.89).
- 52-week range $24.88–$115.52; today's close sits at 57% of that range, 33.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ORKA dips 2.7% to $78.19
- Closed at $78.19, -2.69% vs the prior close of $80.35. Day range $78.18–$80.19, opened at $79.47.
- Volume was 503.10K shares, 0.6x its 50-day average of 888.50K — lighter than usual.
- Price is -16.8% vs its 50-day average ($94.00) and +19.1% vs its 200-day average ($65.67).
- 52-week range $24.46–$115.52; today's close sits at 59% of that range, 32.3% below the 52-week high.
Oct 12, 2026 — ORKA dips 2.1% to $80.35
- Closed at $80.35, -2.14% vs the prior close of $82.11. Day range $79.43–$82.95, opened at $81.81.
- Volume was 547.90K shares, 0.6x its 50-day average of 892.71K.
- Price is -14.8% vs its 50-day average ($94.33) and +22.8% vs its 200-day average ($65.44).
- 52-week range $24.31–$115.52; today's close sits at 61% of that range, 30.4% below the 52-week high.
Oct 9, 2026 — ORKA jumps 6.3% to $82.11
- Closed at $82.11, +6.25% vs the prior close of $77.28. Day range $77.00–$82.24, opened at $77.24.
- Volume was 1.21M shares, 1.3x its 50-day average of 897.37K.
- Price is -13.3% vs its 50-day average ($94.66) and +25.9% vs its 200-day average ($65.19).
- 52-week range $21.66–$115.52; today's close sits at 64% of that range, 28.9% below the 52-week high.
Oct 8, 2026 — ORKA dips 2.8% to $77.28, a 3-month low, 4 down days in a row
- Closed at $77.28, -2.79% vs the prior close of $79.50. Day range $75.83–$80.19, opened at $78.47.
- Volume was 1.23M shares, 1.4x its 50-day average of 888.68K.
- Price is -18.6% vs its 50-day average ($94.97) and +19.0% vs its 200-day average ($64.94).
- 52-week range $20.25–$115.52; today's close sits at 60% of that range, 33.1% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — ORKA dips 0.8% to $79.50, a 3-month low, 3 down days in a row
- Closed at $79.50, -0.85% vs the prior close of $80.18. Day range $78.52–$81.40, opened at $79.01.
- Volume was 809.90K shares, 0.9x its 50-day average of 887.81K.
- Price is -16.5% vs its 50-day average ($95.19) and +22.8% vs its 200-day average ($64.72).
- 52-week range $19.89–$115.52; today's close sits at 62% of that range, 31.2% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — ORKA slides 5.0% to $80.18, a 3-month low
- Closed at $80.18, -4.98% vs the prior close of $84.38. Day range $77.78–$84.94, opened at $84.94.
- Volume was 1.12M shares, 1.3x its 50-day average of 880.26K.
- Price is -16.0% vs its 50-day average ($95.41) and +24.4% vs its 200-day average ($64.46).
- 52-week range $19.74–$115.52; today's close sits at 63% of that range, 30.6% below the 52-week high.
Oct 5, 2026 — ORKA ends flat (-0.2%) to $84.38
- Closed at $84.38, -0.17% vs the prior close of $84.52. Day range $81.83–$85.23, opened at $84.52.
- Volume was 629.60K shares, 0.7x its 50-day average of 879.25K.
- Price is -11.7% vs its 50-day average ($95.61) and +31.4% vs its 200-day average ($64.20).
- 52-week range $19.04–$115.52; today's close sits at 68% of that range, 27.0% below the 52-week high.
Oct 2, 2026 — ORKA rises 1.3% to $84.52, 3 up days in a row
- Closed at $84.52, +1.32% vs the prior close of $83.42. Day range $83.33–$86.00, opened at $84.81.
- Volume was 581.50K shares, 0.7x its 50-day average of 879.94K.
- Price is -11.7% vs its 50-day average ($95.76) and +32.2% vs its 200-day average ($63.92).
- 52-week range $18.43–$115.52; today's close sits at 68% of that range, 26.8% below the 52-week high.
- That makes 3 straight gains.
ORKA latest news & SEC filings
Every SEC filing by or about ORKA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Goncalves Joana converted options/RSUs into 3,500 shares at $6.84 (≈$23.94K) on Oct 15, 2026; now holds 35,271
- Goncalves Joana converted options/RSUs into 3,500 shares at $7.80 (≈$27.30K) on Oct 15, 2026; now holds 38,771
- Goncalves Joana sold 2,853 shares at $73.89 (≈$210.81K) on Oct 15, 2026; now holds 35,918
- Goncalves Joana sold 1,847 shares at $74.69 (≈$137.96K) on Oct 15, 2026; now holds 34,071
- Goncalves Joana sold 1,400 shares at $75.48 (≈$105.68K) on Oct 15, 2026; now holds 32,671
- Goncalves Joana sold 700 shares at $76.67 (≈$53.67K) on Oct 15, 2026; now holds 31,971
- …plus 1 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Agarwal Arjun converted options/RSUs into 8,541 shares at $12.50 (≈$106.76K) on Oct 12, 2026; now holds 22,760
- Agarwal Arjun converted options/RSUs into 1,458 shares at $34.39 (≈$50.14K) on Oct 12, 2026; now holds 24,218
- Agarwal Arjun sold 5,741 shares at $80.03 (≈$459.45K) on Oct 12, 2026; now holds 18,477
- Agarwal Arjun sold 2,100 shares at $80.76 (≈$169.60K) on Oct 12, 2026; now holds 16,377
- Agarwal Arjun sold 1,958 shares at $81.86 (≈$160.27K) on Oct 12, 2026; now holds 14,419
- Agarwal Arjun sold 200 shares at $82.83 (≈$16.57K) on Oct 12, 2026; now holds 14,219
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Klein Lawrence Otto converted options/RSUs into 25,000 shares at $7.80 (≈$195.00K) on Oct 1, 2026; now holds 948,128
- Klein Lawrence Otto sold 16,246 shares at $83.40 (≈$1.35M) on Oct 1, 2026; now holds 931,882
- Klein Lawrence Otto sold 8,554 shares at $84.03 (≈$718.75K) on Oct 1, 2026; now holds 923,328
- Klein Lawrence Otto sold 200 shares at $84.78 (≈$16.96K) on Oct 1, 2026; now holds 923,128
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 28, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 27, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 21, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$41.21M (prior year -$24.57M) (loss widened vs Jun 30, 2025)
Things to know before you trade ORKA
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Sep 5, 2024, Aug 1, 2024. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.38% (largest 6.3%).
- Liquidity: about 1.03M shares (≈$74.42M) trade per day on average.
- 52-week position: $71.93 vs a range of $25.11–$115.52 (52% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Arjun Agarwal sold 533 shares on Sep 21, 2026.
- Latest filings: 8-K Aug 24, 2026; 10-Q Aug 10, 2026; 8-K Aug 10, 2026.
- Share count: 66.21M shares outstanding (Jul 31, 2026), +76.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ORKA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 73.45 | 74.26 | 70.50 | 71.93 | 1.39M |
| Oct 15, 2026 | 75.53 | 77.89 | 73.15 | 73.87 | 1.22M |
| Oct 14, 2026 | 77.37 | 78.57 | 75.41 | 76.68 | 685.30K |
| Oct 13, 2026 | 79.47 | 80.19 | 78.18 | 78.19 | 503.10K |
| Oct 12, 2026 | 81.81 | 82.95 | 79.43 | 80.35 | 547.90K |
| Oct 9, 2026 | 77.24 | 82.24 | 77.00 | 82.11 | 1.21M |
| Oct 8, 2026 | 78.47 | 80.19 | 75.83 | 77.28 | 1.23M |
| Oct 7, 2026 | 79.01 | 81.40 | 78.52 | 79.50 | 809.90K |
| Oct 6, 2026 | 84.94 | 84.94 | 77.78 | 80.18 | 1.12M |
| Oct 5, 2026 | 84.52 | 85.23 | 81.83 | 84.38 | 629.60K |
| Oct 2, 2026 | 84.81 | 86.00 | 83.33 | 84.52 | 581.50K |
| Oct 1, 2026 | 82.85 | 85.00 | 82.50 | 83.42 | 921.00K |
| Sep 30, 2026 | 83.33 | 86.51 | 82.27 | 83.29 | 1.54M |
| Sep 29, 2026 | 83.32 | 84.67 | 81.11 | 82.15 | 1.36M |
| Sep 28, 2026 | 83.94 | 85.95 | 83.22 | 84.19 | 923.30K |
| Sep 25, 2026 | 86.49 | 86.49 | 84.00 | 84.46 | 499.70K |
| Sep 24, 2026 | 88.83 | 89.18 | 82.70 | 85.49 | 1.29M |
| Sep 23, 2026 | 94.08 | 95.81 | 85.00 | 89.93 | 1.99M |
| Sep 22, 2026 | 93.38 | 96.78 | 91.53 | 94.55 | 1.05M |
| Sep 21, 2026 | 95.75 | 96.00 | 91.75 | 93.38 | 1.19M |
About Oruka Therapeutics
Oruka Therapeutics (ORKA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MENLO PARK, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 907654.
ORKA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kristine M Ball | Director | Jun 3, 2026 |
| Carl Dambkowski | Director | Jun 12, 2026 |
| Funds Management Llc Fairmount | Director | Jul 1, 2026 |
| Healthcare Co-Invest Iii L.P. Fairmount | Director | Jul 1, 2026 |
| Healthcare Fund Ii L.P. Fairmount | Director | Jul 1, 2026 |
| Peter Evan Harwin | Director | Jul 1, 2026 |
| Tomas Kiselak | Director | Jul 1, 2026 |
| Lawrence Otto Klein | Chief Executive Officer | Sep 15, 2026 |
| Samarth Kulkarni | Director | Jun 3, 2026 |
| Christopher Nathan Martin | Director | Jun 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Arjun Agarwal | Senior Vice President, Finance | Sep 21, 2026 |
| Larry Todd Edwards | Chief Commercial Officer | Aug 25, 2026 |
| Joana Goncalves | Chief Medical Officer | Sep 15, 2026 |
| Lawrence Otto Klein | Chief Executive Officer | Sep 15, 2026 |
| Paul T Quinlan | General Counsel | Sep 21, 2026 |
| Laura Lee Sandler | Chief Operating Officer | Sep 15, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 21, 2026 | Arjun Agarwal | Sale | 533 | $95.75 |
| Sep 21, 2026 | Arjun Agarwal | Sale | 533 | $95.75 |
| Sep 21, 2026 | Arjun Agarwal | Sale | 533 | $95.75 |
| Sep 21, 2026 | Arjun Agarwal | Sale | 533 | $95.75 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 2,900 | $92.37 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 2,667 | $95.31 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 601 | $94.44 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 3,832 | $93.32 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 2,900 | $92.37 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 2,667 | $95.31 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 601 | $94.44 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 3,832 | $93.32 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 2,900 | $92.37 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 2,667 | $95.31 |
| Sep 21, 2026 | Paul T Quinlan | Sale | 601 | $94.44 |
ORKA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-105.43M | — | $-88.21M |
| Dec 31, 2024 | — | $-83.72M | -3.87 | $-57.84M |
| Dec 31, 2023 | $0 | $-5.34M | -0.37 | $-5.01M |
| Dec 31, 2022 | $0 | $-9.93M | -0.69 | $-10.91M |
| Dec 31, 2021 | $0 | $-19.32M | -1.39 | $-18.76M |
Latest balance sheet: total assets $1.14B, total liabilities $24.84M, cash $268.47M (as of Jun 30, 2026).
ORKA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $105.14 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $68.41 |
| Sep 5, 2024 | 8-K Item 2.02 (results) | — |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| Apr 25, 2024 | 8-K Item 2.02 (results) | — |
| Feb 1, 2024 | 8-K Item 2.02 (results) | — |
| Oct 18, 2023 | 8-K Item 2.02 (results) | — |
| Jul 21, 2023 | 8-K Item 2.02 (results) | — |
| Apr 24, 2023 | 8-K Item 2.02 (results) | — |
| Feb 24, 2023 | 8-K Item 2.02 (results) | — |
| Oct 28, 2022 | 8-K Item 2.02 (results) | — |
| Aug 2, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ORKA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.